Sign in
Enrolling by invitationNo phase

Wearable glucose sensor to check for diabetes after gestational diabetes

Tests a 14-day wearable glucose sensor after pregnancy in women who had gestational diabetes.

Key facts

Who runs it
Wake Forest University Health Sciences
Where
Winston-Salem, United StatesSee the site
Trial code
Registry title
Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening
Status
Enrolling by invitation
People taking part
1,300 people, planned
Started
6 Jul 2026
Expected to end
Jan 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Continuous glucose monitoring for 14 days using the Freestyle LibrePro by Abbott
Record updated
10 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18 or older who had gestational diabetes (diabetes during pregnancy) in their most recent pregnancy. They must be 12-16 weeks after giving birth.

Age
18 Years and older
Sex
Female
Disease stage
Gestational diabetes diagnosed in the most recent pregnancy; now 12-16 weeks after birth.
Biomarker or test result
An order for an Oral Glucose Tolerance Test (OGTT, a sugar-drink blood test) must be in the medical record.

Main reasons for not taking part

  • Diabetes that started before the pregnancy
  • Not speaking English

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • 12-16 weeks postpartum
  • Gestational diabetes Mellitus (GDM) diagnosis in most recent pregnancy
  • Oral Glucose Tolerance Test (OGTT) order placed in the medical record

Who cannot take part

  • Pre-gestational diabetes
  • Non-English language

Where in United States

  • Wake Forest University Health SciencesWinston-Salem, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The oral glucose tolerance test (OGTT) is the standard of care in the postpartum period to screen patients with gestational diabetes mellitus (GDM) for persistent dysglycemia. However, most patients find it burdensome and dread having to do it. Adherence rates are low (18-61%), impeding initiation of follow-up care to improve diabetes-related outcomes in subsequent pregnancies and long-term.

The 3 groups in the trial

  • Postpartum CGMExisting treatment, for comparison

    Postpartum continuous glucose monitoring

    Treatment: Continuous glucose monitoring for 14 days using the Freestyle LibrePro by Abbott

  • Postpartum OGTTNo study treatment, for comparison

    Postpartum oral glucose tolerance test

  • No screeningNo study treatment, for comparison

    No postpartum glucose screening

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening
Plain-language title
Wearable glucose sensor to check for diabetes after gestational diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
10 July 2026